Position Papers

Title
Mammography

This was originally published in NWHN's newsletter, The Women's Health Activist, in the January/February 2007 issue. To receive a sample issue of our newsletter, please email nwhn@nwhn.org.

See also The Myth of the Baseline Mammogram.

By Cynthia Pearson, NWHN Executive Director
Raloxifene for Breast Cancer Prevention - An NWHN Analysis

In April 2006, the National Cancer Institute (NCI) announced preliminary results from STAR, a large clinical trial comparing the effect of raloxifene and tamoxifen on risk of developing breast cancer in postmenopausal women who were considered to be at higher than average risk. The trial was funded by the NCI and Eli Lilly, manufacturer of raloxifene, which is currently marketed under the brand name Evista for prevention and treatment of osteoporosis.
The Myth of the Baseline Mammogram

See also Mammography

While many things about screening mammograms are uncertain, there's at least one thing that is certain: baseline mammograms shouldn't be recommended as a routine part of health care for women. There is complete agreement about this, even among organizations that disagree on almost every other aspect of mammography.